The strategy behind this analysis is the Caviar Cruise screen, a stock screening method rooted in the principles of quality investing. Rather than hunting for deep discounts, quality investors seek companies with durable competitive advantages, consistent growth, and strong profitability, businesses they can own for the long haul. The screen applies a strict set of quantifiable filters, such as revenue and EBIT growth, high returns on invested capital, and low debt relative to cash flow, to narrow down the universe of stocks to those that exhibit these traits. The goal is to identify firms that are not just profitable, but sustainably so, with the ability to reinvest earnings efficiently and generate real cash.
Smith & Nephew PLC - Spon ADR (NYSE:SNN) is a global medical device company specializing in orthopedics, sports medicine, ENT, and advanced wound management. When run through the Caviar Cruise screen, SNN emerges as a candidate that meets several of the core criteria, making it worth a closer look for quality-focused investors.
Recent Performance and Strategy Alignment
Smith & Nephew’s financial history aligns well with the Caviar Cruise screen’s emphasis on consistent, profitable growth. The screen starts with a baseline requirement of at least 5% annual revenue growth over the past five years. SNN’s revenue CAGR over that period stands at 6.07%, just clearing the bar. More impressively, its EBIT CAGR over the same timeframe is 15.80%, significantly outpacing revenue growth. This is a key filter in the screen, as it suggests improving operational efficiency and economies of scale, or pricing power, both hallmarks of a quality business.
The screen also demands a healthy balance sheet. SNN’s Debt-to-Free Cash Flow ratio is 3.90, well below the screen’s upper limit of 5. This means the company could theoretically pay off all its outstanding debt in under four years using its current free cash flow, a sign of financial prudence.
Profitability and Returns on Capital
Return on Invested Capital (ROIC) is arguably the most critical metric for quality investors. It measures how effectively a company puts its capital to work. The Caviar Cruise screen uses the ROIC excluding cash, goodwill, and intangibles, setting a minimum of 15%. Smith & Nephew’s ROICexgc stands at 19.12%, comfortably exceeding that threshold. This indicates that the company is generating a high return on the core capital it deploys in its operations, a strong signal of a competitive moat.
Complementing this is the Profit Quality metric, which assesses how much of net income is converted into free cash flow. SNN’s five-year average is 98.21%, nearly dollar-for-dollar conversion. This is a strong indicator that its reported earnings are backed by real cash, not accounting adjustments. The screen’s threshold of 75% is easily cleared, reinforcing that SNN is mature enough to return cash to shareholders while still reinvesting in growth.
Valuation Metrics
While the Caviar Cruise screen does not filter directly on valuation, a quality investor should always assess price. Based on the fundamental report, SNN appears reasonably priced relative to its peers and the broader market.
- Price/Earnings (P/E) ratio: 22.01, which is slightly below the industry average and below the S&P 500 average of 27.47.
- Price/Forward Earnings: 13.05, signaling a more attractive valuation when looking at expected earnings.
- PEG Ratio (NY): Neutral, suggesting the current P/E is justified by expected growth.
SNN’s enterprise value to EBITDA and price-to-free cash flow ratios are among the cheapest in its industry, ranking in the top deciles. This suggests that while the stock is not a deep value play, it offers a fair entry point for a high-quality business.
Financial Health and Dividend
The company’s financial health is solid. The Altman-Z score of 3.46 indicates low bankruptcy risk, and the current ratio of 2.57 shows ample short-term liquidity. On the dividend front, SNN offers a yield of 2.31%, above both the industry average and the S&P 500 average. The payout ratio of 52.80% is sustainable, and the company has reduced its share count over time, a shareholder-friendly move.
Analyst and Growth Outlook
Looking ahead, analysts expect SNN’s earnings per share to grow by 9.46% annually over the next few years, and revenue to grow by 6.07%. While not explosive, this steady trajectory reinforces the quality narrative: predictable, profitable growth. The EPS growth rate is also accelerating compared to the past five years, a favorable trend.
For a deeper analysis of the full fundamental breakdown, you can review the complete report here.
Summary from the Fundamental Report
Overall, SNN receives a fundamental rating of 6 out of 10 from its peer group of 187 companies in the Health Care Equipment & Supplies industry. The company performs strongly in profitability, with top-quartile scores in return on assets, equity, and invested capital, as well as strong profit and operating margins. Its financial health is above average, though leverage indicators are moderate. Valuation is also a relative strength, with several metrics ranking in the top decile of the industry. Growth is a middling area, with past revenue growth just above 5% but future estimates showing slight acceleration.
More Quality Investing Candidates
If you want to see which other stocks pass this rigorous screen and build your own watchlist of high-quality businesses, you can run the full Caviar Cruise screen for yourself. Find the latest results here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making any financial decisions.